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The Trick of the Tryp
Francis Crick, codiscoverer of the double helix structure of
DNA-the molecule of the genes-has been credited with
defining molecular biology as anything that interests molecu-
lar biologists. What interests George Cross is parasites; in
particular, certain African species of trypanosomes, parasitic
protOzoa that are transmitted to animal hosts by tsetse flies.
In human beings and domestic cattle, trypanosome infection
causes sleeping sickness, for which there are as yet no preven-
tive measures or tOtally safe treatment. On a continent
gripped by catastrophic food shortages, the four million
square miles where the tsetse fly ranges are a precarious envi-
ronment for raising cattle.
Trypanosomes possess a unique mechanism called anti-
genic variation. Like the wily archvillain Moriarty switching
disguises to confound Sherlock Holmes, trypanosomes can
switch their molecular identity to fool detective-defenders of
the mammalian immune system. Dr. Cross has been studying
the "crick of the tryp," as he calls it, for more than a decade.
What he has been learning may eventually lead to more effec-
tive treatments for sleeping sickness. It has already inspired a
new respect for parasites as subjects for basic research.
"Until recently," Dr. Cross says, "parasites have been
largely ignored by molecular biologists. The reasons are both
scientific and social. Parasites have complex life cycles and
they're expensive, difficult, or next to impossible to maintain
George Cross
in the laboratory. So·cially and politically they have been
ignored because the control of parasitic diseases remains pri-
marily a problem of the developing world."
A native of England, Dr. Cross came to Rockefeller Uni-
versity a year ago to establish a laboratory of molecular parasi-
tOlogy. Shortly after, he was named to the newly endowed
Andre and Bella Meyer professorship. At 41, he is a world
leader in his field. His work has recently earned him the
Chalmers Medal of the Royal Society of Tropical Medicine
and Hygiene and the Paul Ehrlich and Ludwig Darmstaedter
Prize of the Paul Ehrlich Foundation in Germany. His
appointment continues a long tradition of parasitology at
Rockefeller, which includes some of the earliest studies of
sleeping sickness.
Dr. Cross and colleague
Christine Clayton in the
hallway outside their labora-
tories which are appropria-
tely housed in Theobald
Smith Hall. The building is
named for a pioneer Rockefel-
ler scientist whose work
helped to lay the foundation
for understanding insect-
transmitted and other infec-
tious diseases. Dr. Clayton, a
transplant from England like
Dr. Cross, has recently
resumed parasitological
research after several years 0/
studying the molecular biol-
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A THOUSAND GENES
What proteins a cell makes are determined by the genes on
the chromosomes within its nucleus. Genes, made of units of
DNA (deoxyribonucleic acid), contain subunits-nucleo-
tides -that code for specific amino acids. When a cell needs a
particular protein, the gene or genes that hold the instruc-
tions for its manufacture are turned on or "expressed," as sci-
entists say. (When genes are not at work they are "silent.")
The revolution in cellular and molecular research in recent
years has been largely the result of the new technologies of
gene splicing-recombinant DNA-and monoclonal antibo-
dies. Explained simply (more simply than achieved), scientists
can cut a sequence of DNA from the nucleus of a eukaryotic
cell, using special enzymes as "shears," and insert it into the
DNA of another cell, usually a bacterium. The bacterium will
then possess and pass on to its progeny the ability to code for
was noted long ago and the involvement of surface antigens
suspected, but no one had been able to find them. It was
assumed that if they existed, they were scarce and chemically
unstable. Applying "straight biochemical analysis and a few
tricks of my own," Dr. Cross found antigens in abundance-
millions of molecules to the cell. He found that they were in
fact stable, and he identified them as glycoproteins: proteins
with a section of carbohydrate attached. Proteins are large
molecules composed of smaller molecules called amino acids.
Some twenty amino acids comprise the alphabet from which
proteins are put together.
"What we wanted to do, first of all," Dr. Cross says, "was to
find out what properties of the variant surface glycoproteins
(VSGs) were responsible for the variation we saw in the living
cell. After we determined that antigenic variation was a func-
tion of the protein and not the carbohydrate content, we
began studying the sequence of the amino acids to develop a
hypothesis for the genetic basis of antigenic variation. We
wondered whether the structure of trypanosome variant anti-
gens might be tIlade up of variable and constant regions. It
turned out, instead, that the entire molecule is variable."
ELUSIVE ANTIGENS
As often happens in science, Dr. Cross's introduction to
what was to become his major work was fortuitous. As a stu-
dent at Cambridge University, his interest was biochemistry.
Later, as a doctoral candidate, he studied the process by which
eukaryotic cells (those of higher animals and protozoa, in con-
trast to bacterial cells) make proteins. He chose a simple para-
sitic protozoan of the trypanosome family because it hap-
pened to be available in the microbiology laboratory in which
he was working. Not until he'd completed his Ph.D. and was
invited to join a new biochemical parasitology unit at Cam-
bridge did he think about parasites as disease organisms
rather than merely as experimental models of general cellular
activity. He turned his attention to Trypanosoma brucei, a spe-
cies of African trypanosome that infects cattle and humans.
Animals, including humans, recognize an infectious cell as a
foreign invader by means of molecules called antigens on the
alien's surface membrane. When the host detects the foreign
presence, it sorts through its own inventory of molecular
weapons, called antibodies, to find a molecule with a shape
that fits the distinctive shape of the antigen, as a key fits a
lock. If a prototype antibody is pinpointed, the cells that pro-
duce it multiply clonally. (Clones are asexually generated off-
spring, identical to the parent cell.) The clones pour forth
antibodies which bind to the antigens and may succeed in kill-
ing the foreign cells before they can proliferate and damage
or kill the host cells. When Trypanosoma brucei invades, the
immune system fails. "While the host antibodies are busy kill-
ing off most of the tryps," Dr. Cross explains, "a small
number of tryps are busy changing antigens. Because the new
antigens are not recognizable to the antibodies manufactured
for the original antigens, the immune system must go through
the whole selection and production process again. Tryps can
switch antigens essentially indefinitely. The antibodies never
catch up and the animal usually dies long before the tryps run
through their antigenic repertoire."
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studying the genes and mem-
branes of malaria parasites.
Digrammatic representation
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the trypanosome surface coat.
The glycoproteins are paired
and closely packed to prevent
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recombinant DNA studies ourselves. I asked Piet Borst if
he'd be interested in working with us since he was also study-
ing trypanosome gene function, although not antigenic varia-
tion. Together we were able to obtain clones coding for the
variant glycoproteins and from that we could go on and get
some idea of the genetic mechanisms." Dr. Cross and Dr.
Borst discovered that the basis of antigenic variation lies in
the ability of Trypanosoma brucei to express alternative genes
for different antigens. What does this mean?
"Many microorganisms can vary antigenically," Dr. Cross
explains. "Bacteria can and so can viruses. They change
through the normal evolutionary process of mutation. Influ-
enza viruses, for example, are continuously evolving new
mutant forms, which is why immunization against one strain
usually doesn't protect against another. The new strains have
altered genes. What makes trypanosomes unique is that they
have evolved a thousand different mutant genes along the line
and kept them all imprinted in the genome, the genetic bun-
dle, of every trypanosome cell. So far as we know, those spe-
cies of trypanosomes with this capability represem the only
situation in nature, outside of the system for producing anti-
bodies in vertebrates, in which there is a large set of genes
the product of the inserted gene. Bacteria are simpler celJs
than eukaryotes. They have fewer genes and they reproduce
quickly. Gene splicing provides a rich and easily retrieved
source of the inserted genes and their products.
Monoclonal antibodies are produced in test tubes by celJ
fusion and cloning techniques. Each monoclonal is a single
molecular species of antibody, arising from a single antibody-
producing cell, and will usually have exquisite specificity for a
single antigen. "This property," says Dr. Cross, "enables us [0
use monoclonals as unsurpassed. reagents for the localization,
assay, ahd extraction of the corresponding antigens."
In 1977 Dr. Cross accepted an offer to lead his own
research team as head of the department of immunochemistry
of the Wellcome Foundation Limited, at its main research
facility in Kent, England. Wellcome is a multinational manu-
facturer of pharmaceutical and biological products. The prof-
its of the company, administered by the Wellcome Trust, are
used to support medical research throughout the world. At
Wellcome, Dr. Cross supervised studies of bacterial, viral,
and parasitic biology. His laboratory also began work toward
a malaria vaccine and played a key role in the development of
clinical-grade leukocyte interferon. (Interferons are small
proteins, produced by cells infected by viruses, that have the
ability to inhibit virus multiplication. They have been under
intense study in recent years as potential therapeutic agents
for various viral diseases and some cancers. Because the body
produces interferons in such infinitesimal quantities, it was
difficult and expensive to study them before the advent of
gene-splicing technology.)
Reflecting the remarkable events unfolding in science at
the time and Dr. Cross's vigorous leadership, the department
expanded its scope and changed its name to molecular biol-
ogy. When he joined, there were eight people in the group.
By the time he left to come to Rockefeller, there were thirty-
six. He himself continued working mainly on trypanosomes
and began what proved to be an extremely productive col-
laboration with the molecular biology laboratory headed by
Dr. Piet Borst at the University of Amsterdam.
"At the time I was setting up at Wellcome," says Dr. Cross,
"we had neither the expertise nor the resources to start
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and gene products whose primary function is to exhibit varia-
bility. It's an extraordinary survival device."
In order to be expressed, a gene for a particular variant gly-
coprotein must first be copied into a special place on the
chromosome called the expression site, where signals start
the production process. "Until recently," says Dr. Cross, "we
weren't able to obtain recombinant clones of an expressed
copy of the .gene, which made it difficult to characterize the
expression site. Our friends in Amsterdam showed conclu-
sively that the expressed copy is inserted in what is called the
telomere, the end region of a chromosome. We got very
excited when we found the expression site because we
thought that we would soon find the promoter signal, the
mechanism that initiates the transcription of the genes from
DNA into RNA. (RNA is another nucleic acid which, in its
"messenger" form, carries genetic instructions it has tran-
scribed from DNA to the site in the cell where proteins are
manufactured.) "We identified a short nucleotide sequence
which is added to the beginning of all VSG RNA transcripts.
We expected it would enable us to pinpoint the location of
the promoter, which we assumed would be adjacent to the
expression site. Unfortunately, that has turned out not to be
the case. After two years of trying, we haven't yet discovered
how the promoter is physically linked to.the gene it's going to
transcribe. Neither we nor anyone else understands exactly
how VSG gene transcription is regulated. It's one of the key
questions right now.
"There are a lot of things we don't know. We know nothing
about how the gene switching is programmed: what deter-
mines when the gene in the expression site will be eliminated
and replaced by a new gene. We don't know whether the
tryps are triggered by an environmental event-something
that happens to them from the outside-or whether there is
an intrinsic timing mechanism that initiates gene-switching
action at predetermined intervals, which is the answer most
researchers in the field currently favor. We can't yet answer
the most obvious question, which is the frequency with which
gene replacement occurs.
"While we're trying to understand the genetics of antigenic
variation," Dr. Cross continues, "we haven't lost sight of the
antigens themselves. As antigenic variation pretty well pre-
cludes the possibility of immunization -of making a vaccine
effective against every antigen form-it may turn out to be
more practical to develop chemotherapy for the disease: to
find ways to attack the antigens themselves, at the surface of
the cell, rather than the genetic machinery; which is why
we're continuing to study the biochemistry of the surface. We
still don't have a complete understanding of the structure of
the glycoproteins and the way in which they're attached to the
cell surface, although since moving to Rockefeller we've
made a major breakthrough in regard to the structural basis of
the antigen-membrane linkage. This linkage is also novel to
tryps and we see it as a potential point for therapeutic
intervention."
DUAL SATISFACTION
Dr. Cross and his colleagues are also studying malaria para-
sites. They are following up observations about some un-
suspected properties of the surface of those cells which first
came to light in the Rockefeller laboratory of Professor Wil-
liam Trager. They came to light because in 1976 Dr. Trager
succeeded in developing a method for cultivating and thereby
observing the parasite in a test tube, something parasitologists
had been trying to do for forty years. Unlike trypanosomal
sleeping sickness, which has a limited geographical range,
malaria is the premiere health problem in large areas of the
world. "But like trypanosomes," says Dr. Cross, "malaria par-
asites exhibit unique phenomena which seem to be the con-
sequences of novel gene products and gene rearrangements.
"In a nutshell, our focus includes both membrane and
genetic phenomena. We're studying them in parasites, but
they are two of the most basic aspects of cell biology no mat-
ter what cell you're studying. The membrane is the interface
between the cell and its environment, and what happens at
the membrane is controlled by the genes.
"What's so exciting about this field to me is that, if you
choose the right parasites, you can have the dual satisfaction
of working with organisms of major medical importance and
on questions of fundamental biological interest." 0
